Protagenic Therapeutics stockholders approve classified board structure; directors re-elected

Protagenic Therapeutics, Inc.new

At Sep 29 annual meeting, all six director nominees elected with votes ranging from 8.37M to 8.88M for each.
Stockholders approved classified board amendment (8.82M for, 150.9K against); filed with Delaware on Oct 1, 2021.
Board classified into three classes: Class I (Buell, Stein) term expiring 2022, Class II (Barrage, Silverman) 2023, Class III (Armen, Corvese) 2024.
MaloneBailey LLP ratified as independent auditor for FY2021 (10.60M for, 2.8K against).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.